Full Version
|
Search
The Irish Medicines Board - www.imb.ie
Home
About Us
Consultation
Events
Glossary
Legislation
Links
News
Publications
Recruitment
Register
Safety & Quality
Human Medicines
Veterinary
Medical Devices
Blood, Tissues, Organs
Cosmetics
Patients & Public
Home
»
Publications
»
Revlimid (lenalidomide) – risk of venous and arterial thromboembolic events
Your Selection
[x]
Letter
: R
[x] Remove All Filters
By Product
Blood, Tissues & Cells (1)
Human medicines (37)
Medical devices (1)
Veterinary (4)
By Audience / Stakeholder Group
All Stakeholders (3)
Healthcare professionals (34)
Industry (7)
By Document Type
Direct Healthcare Professional Communication (29)
Forms & Templates (4)
Guidance (3)
Safety Updates & Reports (6)
By Service
Clinical Trials (2)
Licensing – Medicines (2)
Product Classification (3)
Reporting Safety & Quality issues (1)
Revlimid (lenalidomide) – risk of venous and arterial thromboembolic events
09 May 2011
Tags:
Human medicines
Healthcare professionals
Safety Updates & Reports
2011
Revlimid (lenalidomide) – risk of venous and arterial thromboembolic events
« View Publications List
Provide Feedback
RSS Feeds
IMB Publications RSS Feed